The company has substantially advanced this progress of the new treatment for cardiac amyloidosis, utilizing the compound. Initial patient information suggests significant improvements for individuals suffering from a serious illness. This focus underscores BridgeBio's focus to managing unmet medical demands in the heart space. Attruby: BridgeBio'